ArticleAustralian veterinary journal2025
Development and characterisation of a fully recombinant competition ELISA for the diagnosis of foot-and-mouth disease virus infection.
Article in Australian veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and characterisation of a fully recombinant competition ELISA for the diagnosis of foot-and-mouth disease virus infection.Australian veterinary journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Infection of livestock by foot-and-mouth disease (FMD) virus (FMDV) has serious economic implications due to productivity losses and trade restrictions. In countries that are free from foot and mouth disease, the World Organisation for Animal Health (WOAH) provides two proof of freedom from disease status categories; namely, FMD-free without using vaccination or FMD-free with use of vaccination. Serological surveillance of livestock after an incursion forms one part of a country's emergency disease response plan as it is an important condition in attaining a WOAH declaration of freedom from FMDV. The development of a competition enzyme-linked immunosorbent assay using recombinant antigen (FMDV 3B-maltose-binding protein fusion) and recombinant antibody (anti-FMDV 3B scFv-alkaline phosphatase fusion) reagents from two independently developed tests is described. The characteristics of the recombinant reagents and performance of the assay are presented and provide evidence of an improved, fully recombinant, competition ELISA suitable for sensitive and specific identification of antibodies to FMDV non-structural protein 3B in cattle sera, making it suitable for differentiating infected and vaccinated animals (DIVA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.